Polaryx Therapeutics Inc PLYX

Morningstar Rating
$1.61 +0.01 (0.63%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PLYX is trading at a LOCK|R>#s& premium.
Price
$1.63
Fair Value
LOCK|q?S&!$
Uncertainty
LOCK|^C P>SQ
1-Star Price
LOCK|#v%gP&^
5-Star Price
LOCK|@?X?&K
Economic Moat
LOCK|FmMF
Capital Allocation
—

News

Trading Information

Previous Close Price
$1.60
Day Range
$1.61–1.68
52-Week Range
$1.56–48.91
Bid/Ask
$1.61 / $1.77
Shares Outstanding
49.85M
Market Cap
$80.25M
Volume/Avg
22,334 / 40,064

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
—

Valuation

Metric
PLYX
Price/Earnings (Normalized)
—
Price/Book Value
10.54
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
PLYX
Quick Ratio
8.45
Current Ratio
8.62
Interest Coverage
—
Quick Ratio
PLYX

Profitability

Metric
PLYX
Return on Assets (Normalized)
−100.54%
Return on Equity (Normalized)
−114.11%
Return on Invested Capital (Normalized)
−114.11%
Return on Assets
PLYX

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|v?rnXF!LOCK|P>?l$136B
Regeneron Pharmaceuticals Inc
REGN
LOCK|>X<vNmvLOCK|#!@CV$98B
Moderna Inc
MRNA
LOCK|#r>X!lLOCK|zfN$80B
argenx SE ADR
ARGX
LOCK|Q<t$TlLOCK|ZS$59B
BeOne Medicines Ltd ADR
ONC
LOCK|&bjZ%!LOCK|fFV$47B
Royalty Pharma PLC Class A
RPRX
LOCK|!K$JM^<LOCK|xQ<>$31B
Incyte Corp
INCY
LOCK|c$?pg>&LOCK|Rc$24B
BioNTech SE ADR
BNTX
LOCK|%M%<H>$LOCK|J?<$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|?K$sb>LOCK|yf$h$20B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|>bBL&XLOCK|H^$16B

Sponsor Center